Völker W, Kannengiesser U, Majewski A, Vasterling H W
Geburtshilfe Frauenheilkd. 1978 Sep;38(9):735-43.
The public discussion and the discussion among gynaecologists about the possible increased risk to develop carcinoma of the endometrium following post menopausal treatment with estrogens has lead to insecurity and restricted attitudes in the prescriptions of estrogens. In a statistic comparison of matched pairs of 130 cases of carcinoma of the endometrium with an equal number of selected control cases the following findings were elucidated: 1. Any estrogen preparations do not increase the relative risk for the development of carcinoma of the endometrium. 2. Differentiation into conjugated estrogens, estriol, oral contraceptives and various other estrogen compounds showed a similar trend. 3. Estrogen-androgen compounds and estrodiol compounds did not increase the relative risk for endometrial carcinoma. 4. The relative risk does not increase by prolonged ingestion of estrogen preparations in general and not for conjugated estrogens especially. 5. In the presence of other risk factors such as nulligravity, hypertension, obesity the relative risk for the development of carcinoma of the endometrium is significantly decreased when estrogens were taken, especially when the coincidental risk factor to estrogen ingestion was obesity. The above results suggest that the restraint in the prescription of estrogen for fear of endometrial carcinoma is not justified.
关于绝经后使用雌激素治疗可能增加子宫内膜癌发病风险的公众讨论以及妇科医生之间的讨论,导致了在雌激素处方方面的不安全感和受限态度。在对130例子宫内膜癌病例与同等数量的选定对照病例进行配对的统计比较中,得出了以下结果:1. 任何雌激素制剂都不会增加子宫内膜癌发生的相对风险。2. 分化为共轭雌激素、雌三醇、口服避孕药和各种其他雌激素化合物显示出类似趋势。3. 雌激素 - 雄激素化合物和雌二醇化合物不会增加子宫内膜癌的相对风险。4. 一般来说,长期服用雌激素制剂不会增加相对风险,特别是共轭雌激素。5. 在存在其他风险因素如未生育、高血压、肥胖的情况下,服用雌激素时子宫内膜癌发生的相对风险会显著降低,尤其是当与雌激素摄入同时存在的风险因素是肥胖时。上述结果表明,因担心子宫内膜癌而对雌激素处方加以限制是不合理的。